Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Corrigendum to ``Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition'' [Cancer Genet. 221(2018) 38-45].

Ripamonti CB, Manoukian S, Peissel B, Azzollini J, Carcangiu ML, Radice P.

Cancer Genet. 2018 Dec;228-229:128. doi: 10.1016/j.cancergen.2018.06.001. Epub 2018 Jun 29. No abstract available.

PMID:
30554731
2.

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy.

Triulzi T, Forte L, Regondi V, Di Modica M, Ghirelli C, Carcangiu ML, Sfondrini L, Balsari A, Tagliabue E.

Oncoimmunology. 2018 Sep 21;8(1):e1512942. doi: 10.1080/2162402X.2018.1512942. eCollection 2019.

3.

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Tessari A, Pilla L, Silvia D, Duca M, Paolini B, Carcangiu ML, Mariani L, de Braud FG, Cresta S.

Breast. 2018 Dec;42:68-73. doi: 10.1016/j.breast.2018.08.106. Epub 2018 Aug 29.

PMID:
30189381
4.

Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.

Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A.

J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1.

5.

Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer.

Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S.

Breast Care (Basel). 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12.

6.

Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition.

Ripamonti CB, Manoukian S, Peissel B, Azzollini J, Carcangiu ML, Radice P.

Cancer Genet. 2018 Feb;221:38-45. doi: 10.1016/j.cancergen.2017.12.001. Epub 2017 Dec 29. Erratum in: Cancer Genet. 2018 Dec;228-229:128.

PMID:
29405995
7.

Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.

Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, De Cecco L, Rizzetti MG, Zanframundo A, Aiello A, Carcangiu ML, Gloghini A, Ferrero S, Licitra L, Greco A, Fugazzola L, Locati LD, Borrello MG.

Endocr Relat Cancer. 2018 Mar;25(3):217-231. doi: 10.1530/ERC-17-0389. Epub 2018 Jan 3.

PMID:
29298817
8.

Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study.

Martelli G, Miceli R, Folli S, Guzzetti E, Chifu C, Maugeri I, Ferranti C, Bianchi G, Capri G, Carcangiu ML, Paolini B, Agresti R, Ferraris C, Piromalli D, Greco M.

Eur J Surg Oncol. 2017 Nov;43(11):2012-2020. doi: 10.1016/j.ejso.2017.07.023. Epub 2017 Aug 10.

PMID:
28912071
9.

Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.

Maltese G, Fontanella C, Lepori S, Scaffa C, Fucà G, Bogani G, Provenzano S, Carcangiu ML, Raspagliesi F, Lorusso D.

Oncology. 2018;94(1):1-6. doi: 10.1159/000479818. Epub 2017 Sep 5.

PMID:
28869928
10.

Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast.

Gennaro M, De Santis MC, Mariani L, Lo Vullo S, Cappelletti V, Agresti R, Cortinovis U, Paolini B, Di Cosimo S, Carcangiu ML, Daidone MG, Lozza L.

Breast. 2017 Oct;35:63-68. doi: 10.1016/j.breast.2017.06.010. Epub 2017 Jun 23.

PMID:
28651115
11.

Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy".

Bogani G, Signorelli M, Chiappa V, Carcangiu ML, Martinelli F, Paolini B, Leone Roberti Maggiore U, Gennaro M, Borghi C, Scaffa C, Ditto A, Lorusso D, Raspagliesi F.

J Minim Invasive Gynecol. 2017 Nov - Dec;24(7):1243-1244. doi: 10.1016/j.jmig.2017.05.020. Epub 2017 Jun 23. No abstract available.

PMID:
28648838
12.

Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience.

Bogani G, Tagliabue E, Signorelli M, Chiappa V, Carcangiu ML, Paolini B, Casarin J, Scaffa C, Gennaro M, Martinelli F, Borghi C, Ditto A, Lorusso D, Raspagliesi F.

J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842. doi: 10.1016/j.jmig.2017.04.017. Epub 2017 May 4.

PMID:
28479170
13.

Involvement of AF1q/MLLT11 in the progression of ovarian cancer.

Tiberio P, Lozneanu L, Angeloni V, Cavadini E, Pinciroli P, Callari M, Carcangiu ML, Lorusso D, Raspagliesi F, Pala V, Daidone MG, Appierto V.

Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.

14.

Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies.

Azzollini J, Pesenti C, Ferrari L, Fontana L, Calvello M, Peissel B, Portera G, Tabano S, Carcangiu ML, Riva P, Miozzo M, Manoukian S.

PLoS One. 2017 Feb 15;12(2):e0171663. doi: 10.1371/journal.pone.0171663. eCollection 2017.

15.

Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study.

Agresti R, Sandri M, Gennaro M, Bianchi G, Maugeri I, Rampa M, Capri G, Carcangiu ML, Trecate G, Riggio E, Lozza L, de Braud F.

Clin Breast Cancer. 2017 Jun;17(3):219-231. doi: 10.1016/j.clbc.2016.12.003. Epub 2016 Dec 24.

PMID:
28087389
16.

Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.

Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, de Braud F, Di Cosimo S.

Breast Cancer. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6. Epub 2017 Jan 5.

PMID:
28058615
17.

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M.

Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935.

18.

Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer.

Merlino G, Miodini P, Paolini B, Carcangiu ML, Gennaro M, Dugo M, Daidone MG, Cappelletti V.

Microarrays (Basel). 2016 May 18;5(2). pii: E10. doi: 10.3390/microarrays5020010.

19.

Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.

Lozneanu L, Pinciroli P, Ciobanu DA, Carcangiu ML, Canevari S, Tomassetti A, Căruntu ID.

Anticancer Res. 2016 Aug;36(8):4155-63.

PMID:
27466525
20.

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.

Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group.

Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9.

21.

Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy.

Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, Gronchi A, Raspagliesi F.

J Minim Invasive Gynecol. 2016 May-Jun;23(4):647-9. doi: 10.1016/j.jmig.2016.01.021. Epub 2016 Feb 2.

PMID:
26851127
22.

Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.

Dorman SN, Baranova K, Knoll JH, Urquhart BL, Mariani G, Carcangiu ML, Rogan PK.

Mol Oncol. 2016 Jan;10(1):85-100. doi: 10.1016/j.molonc.2015.07.006. Epub 2015 Aug 22.

23.

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.

Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E.

Oncotarget. 2015 Sep 29;6(29):28173-82. doi: 10.18632/oncotarget.4405.

24.

Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case.

Ditto A, Martinelli F, Bogani G, Gasparri ML, Donato VD, Paolini B, Carcangiu ML, Lorusso D, Raspagliesi F.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000386.

PMID:
26166228
25.

Management of breast cancer after Hodgkin's lymphoma and paediatric cancer.

Terenziani M, Massimino M, Magazzù D, Gandola L, Capri G, Carcangiu ML, Catania S, Di Russo A, Gennaro M, Meazza C, Podda M, Schiavello E, Valagussa P.

Eur J Cancer. 2015 Sep;51(13):1667-74. doi: 10.1016/j.ejca.2015.05.024. Epub 2015 Jun 16.

PMID:
26092639
26.

Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.

Huang X, Dugo M, Callari M, Sandri M, De Cecco L, Valeri B, Carcangiu ML, Xue J, Bi R, Veneroni S, Daidone MG, Ménard S, Tagliabue E, Shao Z, Wu J, Orlandi R.

Cancer Med. 2015 Jul;4(7):1016-30. doi: 10.1002/cam4.442. Epub 2015 Mar 18.

27.

Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.

Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafrè S, Carcangiu ML, Zonfrillo M, Nicotera G, Sica L, De Braud F, Pierimarchi P.

Oncotarget. 2015 Mar 10;6(7):5275-91.

28.

¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.

Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri E, Maugeri I, Rampa M, Carcangiu ML, Trecate G, Pascali C, Bogni A, Martelli G, de Braud F.

Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30. doi: 10.1007/s00259-015-2995-8. Epub 2015 Feb 12.

PMID:
25673053
29.

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE.

Cancer Lett. 2015 Apr 10;359(2):269-74. doi: 10.1016/j.canlet.2015.01.024. Epub 2015 Jan 29.

PMID:
25641339
30.

Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.

Callari M, Musella V, Di Buduo E, Sensi M, Miodini P, Dugo M, Orlandi R, Agresti R, Paolini B, Carcangiu ML, Cappelletti V, Daidone MG.

Mol Oncol. 2014 Oct;8(7):1278-89. doi: 10.1016/j.molonc.2014.04.010. Epub 2014 May 4.

31.

Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.

Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E.

Breast. 2014 Aug;23(4):334-40. doi: 10.1016/j.breast.2014.01.001. Epub 2014 Jan 31.

PMID:
24485802
32.

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).

Agresti R, Martelli G, Sandri M, Tagliabue E, Carcangiu ML, Maugeri I, Pellitteri C, Ferraris C, Capri G, Moliterni A, Bianchi G, Mariani G, Trecate G, Lozza L, Langer M, Rampa M, Gennaro M, Greco M, Menard S, Pierotti MA.

Cancer. 2014 Mar 15;120(6):885-93. doi: 10.1002/cncr.28499. Epub 2013 Dec 5.

33.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization.

Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P, Tagliabue E.

Int J Cancer. 2014 Jun 15;134(12):2789-97. doi: 10.1002/ijc.28608. Epub 2013 Nov 30.

34.

Ex vivo MRI evaluation of breast tumors: a novel tool for verifying resection of nonpalpable only MRI detected lesions.

Agresti R, Trecate G, Ferraris C, Valeri B, Maugeri I, Pellitteri C, Martelli G, Migliavacca S, Carcangiu ML, Bohm S, Maffioli L, Vergnaghi D, Panizza P.

Breast J. 2013 Nov-Dec;19(6):659-63. doi: 10.1111/tbj.12183. Epub 2013 Sep 19.

PMID:
24102850
35.

The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.

Liliac L, Carcangiu ML, Canevari S, Căruntu ID, Ciobanu Apostol DG, Danciu M, Onofriescu M, Amălinei C.

Rom J Morphol Embryol. 2013;54(1):17-27.

36.

The oncofetal protein IMP3: a novel biomarker and triage tool for premalignant atypical endometriotic lesions.

Vercellini P, Cribiù FM, Del Gobbo A, Carcangiu ML, Somigliana E, Bòsari S.

Fertil Steril. 2013 Jun;99(7):1974-9. doi: 10.1016/j.fertnstert.2013.02.002. Epub 2013 Mar 7.

PMID:
23473990
37.

Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.

Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E.

PLoS One. 2013;8(2):e56761. doi: 10.1371/journal.pone.0056761. Epub 2013 Feb 18.

38.

First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.

Ripamonti CB, Colombo M, Mondini P, Siranoush M, Peissel B, Bernard L, Radice P, Carcangiu ML.

BMC Cancer. 2013 Feb 1;13:46. doi: 10.1186/1471-2407-13-46.

39.

Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.

Secreto G, Venturelli E, Meneghini E, Carcangiu ML, Paolini B, Agresti R, Pellitteri C, Berrino F, Gion M, Cogliati P, Saragò G, Micheli A.

BMC Cancer. 2012 Dec 14;12:599. doi: 10.1186/1471-2407-12-599.

40.

Benign epithelial inclusions in axillary lymph nodes: report of 18 cases and review of the literature.

Fellegara G, Carcangiu ML, Rosai J.

Am J Surg Pathol. 2011 Aug;35(8):1123-33. doi: 10.1097/PAS.0b013e3182237985. Review.

PMID:
21753696
41.

A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer.

Pusceddu S, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M, Buzzoni R.

Crit Rev Oncol Hematol. 2012 Feb;81(2):185-95. doi: 10.1016/j.critrevonc.2011.03.008. Epub 2011 Apr 23. Review.

PMID:
21515070
42.

Angiosarcoma of the breast and vascular endothelial growth factor receptor.

Gennaro M, Valeri B, Casalini P, Carcangiu ML, Gronchi A, Conti AR, Agresti R, Greco M.

Tumori. 2010 Nov-Dec;96(6):930-5.

PMID:
21388054
43.

Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.

Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, Yu Y.

BMC Cancer. 2010 Jul 20;10:378. doi: 10.1186/1471-2407-10-378.

44.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359
45.

Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.

Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P.

Int J Surg Pathol. 2010 Feb;18(1):21-6. doi: 10.1177/1066896909332117. Epub 2009 May 14.

PMID:
19443869
46.

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A.

J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2.

PMID:
19255331
47.

Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.

Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L.

Ann Oncol. 2009 Apr;20(4):741-5. doi: 10.1093/annonc/mdn695. Epub 2009 Feb 3.

PMID:
19190075
48.

Variant HNF1 modulates epithelial plasticity of normal and transformed ovary cells.

Tomassetti A, De Santis G, Castellano G, Miotti S, Mazzi M, Tomasoni D, Van Roy F, Carcangiu ML, Canevari S.

Neoplasia. 2008 Dec;10(12):1481-92, 3p following 1492.

49.

Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping.

Xu ML, Yang B, Carcangiu ML, Hui P.

Mod Pathol. 2009 Feb;22(2):232-8. doi: 10.1038/modpathol.2008.165. Epub 2008 Sep 26.

50.

Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report.

Pusceddu S, Bajetta E, Buzzoni R, Carcangiu ML, Platania M, Del Vecchio M, Ditto A.

Int J Gynecol Pathol. 2008 Oct;27(4):596-600. doi: 10.1097/PGP.0b013e31817323c4.

PMID:
18753958

Supplemental Content

Loading ...
Support Center